Novartis axes asthma drug fevipiprant after more trial woes

It’s nearly always bad news when pharma companies provide an “update” about a trial – and the statement today from Novartis about its asthma drug fevipiprant must make bleak reading for all

Chasing Mylan, Hikma tries again with rejected generic Advai...

GSK aims to get triple therapy approved for asthma in US

GlaxoSmithKline and development partner Innoviva have filed a dossier with the FDA, in a bid to get their triple therapy approved to keep asthma at bay.

Augmented reality app helps kids improve asthma inhaler tech...

A new augmented reality app aims to help kids improve their asthma inhaler technique in a bid to reduce emergency hospital admissions.

AZ's asthma and diabetes drugs get label boosts in EU

Two of AstraZeneca’s most important drugs have received a boost, after European regulators backed a pen allowing people to inject themselves with respiratory drug Fasenra, and agreed that c

Sanofi/Regeneron asthma trial casts doubt on IL-33 class pro...